Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 12 Month, Randomized, Open-label, Multicenter, Study to Assess the Long Term Safety of Aliskiren 150 mg Alone and 300 mg Alone or With the Optional Addition of Hydrochlorothiazide (12.5 mg or 25 mg) in Patients With Essential Hypertension.

NCT00219037 is registered in ClinicalTrials.gov with Novartis as lead sponsor.

NCT NCT00219037
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00219037 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 12 Month, Randomized, Open-label, Multicenter, Study to Assess the Long Term Safety of Aliskiren 150 mg Alone and 300 mg Alone or With the Optional Addition of Hydrochlorothiazide (12.5 mg or 25 mg) in Patients With Essential Hypertension.
Lead sponsor
Novartis
Phase
Phase 3
Overall status
Completed
Start date
June 30, 2004
Completion date
October 31, 2005
Enrollment
1,955 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hypertension